RT Journal Article
SR Electronic
T1 Estrogen Receptor-negative Ductal Carcinoma <em>In Situ</em> (DCIS) of the Breast – an Institutional Review of Outcomes
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4031
OP 4036
DO 10.21873/anticanres.16591
VO 43
IS 9
A1 EWA ZABROCKA
A1 BERNARD NEWMAN
A1 GABRIELLE LEVEY
A1 KEITH SWEENEY
A1 JAYMIE OENTORO
A1 SAMUEL RYU
A1 ALEXANDER STESSIN
YR 2023
UL http://ar.iiarjournals.org/content/43/9/4031.abstract
AB Background/Aim: Estrogen receptor (ER)-negative [ER(−)] invasive breast cancers (IBCs) are known to be more aggressive than their ER(+) counterparts. This is less well defined for ductal carcinoma in situ (DCIS). This study investigated the outcomes following the treatment of ER(−) DCIS. Patients and Methods: A total of 103 ER(−) DCIS patients diagnosed between 2004-2018 were retrospectively analyzed. Median follow-up was 63.9 months. Statistical analysis included descriptive statistics, non-parametric tests, T-test, logistic regression. The outcomes were compared to a group of 102 ER(+) DCIS patients from our institution. Results: Any breast event (BE) occurred in 10 (9.7%) patients at a median of 3.2 (1.7-7.2) years. The incidence of ipsilateral breast events (IBEs) was 5.8% (6/103). All IBE cases were ER(−) DCIS. All (n=4) contralateral breast events (CBEs) were ER(+) including 3 IBCs. Cumulative incidence of any BEs at 1, 2, and 5 years was 0%, 1.1%, and 9.1%, respectively. Among patients with ER(−) DCIS who developed BE, breast conserving surgery (BCS) had been performed for the initial DCIS in 90% of cases. In those without any BE, the BCS rate (vs. mastectomy) was 58.1% (p=0.08). Adjuvant radiotherapy after BCS was used less often among patients with vs. without subsequent BE (55.5% vs. 77.4%) (p=0.22). Predictors for BE occurrence were not identified. The incidence of any BE among patients with ER(+) DCIS was 6.9% and was not significantly different compared to ER(−) DCIS group (p=0.46). Conclusion: ER(−) DCIS outcomes were similar to our institutional ER-positive DCIS group and the previously reported ones for predominantly ER-positive DCIS cohorts.